(a) what is the specific exclusion criteria which is fulfilled by Isoxuprine Hcl., Polymixin-B Sulphate, Flucort, Phenformin, Durabolin, Avapyrazone Pancretin and Glipizide;

(b) whether it is a fact that these drugs have been wrongly excluded from price control by Kelkar Committee as nothing is based on factual details;

(c) whether it is also a fact that as per DPCO 1987, the manufacturers have to provide sales turn-over of price decontrolled drugs formulations;

(d) if so, the details of proformas under which sales turn-over is to be provided; and

(e) what are the details of sales turnover of the above drugs as well as of the two major selling brands of formulations of each drug during 1986 and 1987 along with their price before DPCO, 1987 and at present?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) The Kelkar Committee adopted following five criterias for excluding drugs from price control:—

(i) Exclude those drugs which are not produced in India, provided that the consumption is not significant either now or in the near future.

(ii) To exclude those drugs the turn over of which has been less than rupees fifty lakhs in 1986.

(iii) To exclude all new drugs for which process of manufacture were developed indigenously from the price control list at least for the first five years.

(iv) To exclude those life-saving drugs and pharmaceutical products whose availability is far more important than the price. As the nature of demand is such that it is required less frequently but its non-availability is fatal. The notable examples of such categories are sera and vaccines.

(v) Exclude those pharmaceutical products of drugs where the domestic production structure is so competitive that there is little possibility that the consumer will be over-charged compared to the cost of production.

(c) and (b) The manufacturers are required to furnish information in Form-4 and 6 as specified under DPCO, 1987.

(e) Sales turn-over of individual formulation is not monitored.

Prices of Flucort range of formulations

3289. SHRI BEKAL UTSAHI: Will the Minister of INDUSTRY be pleased to state:

(a) what was the price of Flucort range of formulations fixed under DPCO, 1979 and what was the price being charged by the Company;

(b) whether it is a fact that the company overcharged the prices and also imported the bulk drug at a price much lower than the price on which formulations were based;

(c) whether they were issued any show-cause notice for over-charging the prices and for the recovery under the Drug prices Equalisation Account and if so, when they were issued with such notices; and

(d) what is the present position in this regard?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) As per the provisions of DPCO, 1987 Flucort range of formulations are price decontrolled and the concerned manufacturer is free to revise the prices.

(b) No such instance has come to the notice of the Government.

(c) and (d) Do not arise in view of reply to part (b) above.

Prices of Chloramphenicol formulation

3290. SHRI CHANDRIKA PRASAD TRIPATHI: Will the Minister of INDUSTRY be pleased to state:

(a) what were the prices of Chloramphenicol formulations which Parke Davis was charging at the time of filing the writ and what were the notified price

(b) how long the Company continued to charge its own prices and what happened to the difference payable by the Company;

(c) what are the approved prices and the prices charged by the Company for multi-vitamin formulations; and

(d) what are the reasons for which price approval for multi-vitamins have been given to Pfizer and not to other companies?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) The prices fixed by the Government for Chloramphenicol formulations under DPCO, 1979 were not stayed by the Court and M/s. Parke Davis had been following the prices fixed by the Government from time to time.

(c) The required details to the extent available are given in the statement (*See below*).

(d) M/s. Pfizer had given an undertaking to implement the prices to be fixed by the Government with 100 per cent MAPE on the same ex-factory cost as allowed for such formulations under DPCO. 1979. Other companies who had challenged the prices fixed by the Government did not give such undertaking.

Statement

Sl. No.	Name of the Formulation	Pack Size	Price fixed by the Govt. under DPCO, 1979	Current Price
1	Ferradol Ph.	454gm.	13.04	18.51
2	Ferradol Ph.	1.25Kg.	28.36	44.34
3	Natabec Capsules Ph.	20's	3.02	4.83
4	Natabec Capsules Ph.	30's	4.37	Not being marketed at present
5	Natabec Capsules Ph.	100's	12.71	16.15
6	Myadec Capsules Th.	20's	5.98	8.42
7	Myadec Capsules Th.	30's	8.81	Not being marketed
8	Myadec Capsules Th.	100's	27.44	34.24
9	Taka Combex Elexir Ph.	114ml	6.79	13.83
10	Taka Combex Kapseals Th.	25's	5.80	Presently not being marketed
11	Taka Combex Kapseals Th.	30's	6.98	Do.
12	Taka Combex Kapseals Th.	75's	16.20	Do.
13	Taka Combex Kapseals Th.	100's	20.09	Do.
14	Paladac Th.	114ml	6.17	8.46
	ABDEC Drops Pd.	15ml	3.43	4.12
	Livibron Th.	228ml	8.23	9.95